46-60 of 360
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD
Javier Cortes, MD, PhD
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
Tiffany Traina, MD
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD
Javier Cortes, MD, PhD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CEPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
- advertisement
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME/CECracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CEThe Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
